Literature DB >> 28882978

Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer.

Toshiya Maekura1, Maiko Naito2, Masahiro Tahara2, Naoya Ikegami2, Yohei Kimura2, Shoko Sonobe2, Takehiko Kobayashi2, Taisuke Tsuji2, Shojiro Minomo2, Akihiro Tamiya2, Shinji Atagi3.   

Abstract

BACKGROUND/AIM: Although immune checkpoint inhibitors play an important role in the therapy of lung cancer, they are associated with various immune-related adverse events and predictive factors of them are unclear. In this study, we investigated predictive factors of nivolumab-induced hypothyroidism which is one of the adverse events in patients with lung cancer. PATIENTS AND METHODS: Patients with non-small-cell lung cancer who were administered nivolumab at our hospital between December 2015 and May 2016 were retrospectively enrolled. The thyroid-stimulating hormone, free triiodothyronine, free thyroxine, thyroid peroxidase (TPO) antibody, and thyroglobulin antibody levels of each patient were analyzed.
RESULTS: Of the 64 patients enrolled, 5 (7.8%) developed hypothyroidism after treatment with nivolumab. The TPO and thyroglobulin antibodies were significantly positive in patients who developed primary hypothyroidism.
CONCLUSION: TPO and thyroglobulin antibody levels at baseline may be predictive of hypothyroidism. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Hypothyroidism; lung cancer; nivolumab; thyroglobulin; thyroid peroxidase

Mesh:

Substances:

Year:  2017        PMID: 28882978      PMCID: PMC5656848          DOI: 10.21873/invivo.11166

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  21 in total

Review 1.  A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors.

Authors:  T W Chen; A R Razak; P L Bedard; L L Siu; A R Hansen
Journal:  Ann Oncol       Date:  2015-04-17       Impact factor: 32.976

2.  Hypothyroidism in Cancer Patients on Immune Checkpoint Inhibitors with anti-PD1 Agents: Insights on Underlying Mechanisms.

Authors:  M Alhusseini; J Samantray
Journal:  Exp Clin Endocrinol Diabetes       Date:  2017-01-10       Impact factor: 2.949

Review 3.  Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.

Authors:  Mabel Ryder; Margaret Callahan; Michael A Postow; Jedd Wolchok; James A Fagin
Journal:  Endocr Relat Cancer       Date:  2014-03-07       Impact factor: 5.678

4.  Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.

Authors:  Ichiro Yamauchi; Yoriko Sakane; Yorihide Fukuda; Toshihito Fujii; Daisuke Taura; Masakazu Hirata; Keisho Hirota; Yohei Ueda; Yugo Kanai; Yui Yamashita; Eri Kondo; Masakatsu Sone; Akihiro Yasoda; Nobuya Inagaki
Journal:  Thyroid       Date:  2017-06-21       Impact factor: 6.568

5.  Nivolumab-induced thyroid dysfunction.

Authors:  Ryota Tanaka; Yasuhiro Fujisawa; Hiroshi Maruyama; Yasuhiro Nakamura; Koji Yoshino; Mikio Ohtsuka; Manabu Fujimoto
Journal:  Jpn J Clin Oncol       Date:  2016-03-23       Impact factor: 3.019

Review 6.  Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.

Authors:  Jeryl Villadolid; Asim Amin
Journal:  Transl Lung Cancer Res       Date:  2015-10

7.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Authors:  Naiyer A Rizvi; Julien Mazières; David Planchard; Thomas E Stinchcombe; Grace K Dy; Scott J Antonia; Leora Horn; Hervé Lena; Elisa Minenza; Bertrand Mennecier; Gregory A Otterson; Luis T Campos; David R Gandara; Benjamin P Levy; Suresh G Nair; Gérard Zalcman; Jürgen Wolf; Pierre-Jean Souquet; Editta Baldini; Federico Cappuzzo; Christos Chouaid; Afshin Dowlati; Rachel Sanborn; Ariel Lopez-Chavez; Christian Grohe; Rudolf M Huber; Christopher T Harbison; Christine Baudelet; Brian J Lestini; Suresh S Ramalingam
Journal:  Lancet Oncol       Date:  2015-02-20       Impact factor: 41.316

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

9.  A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.

Authors:  David Planchard; Takashi Yokoi; Michael J McCleod; Jürgen R Fischer; Young-Chul Kim; Marc Ballas; Kelvin Shi; Jean-Charles Soria
Journal:  Clin Lung Cancer       Date:  2016-03-17       Impact factor: 4.785

Review 10.  Thyroid dysfunction as an unintended side effect of anticancer drugs.

Authors:  Francesco Torino; Agnese Barnabei; Rosamaria Paragliola; Roberto Baldelli; Marialuisa Appetecchia; Salvatore Maria Corsello
Journal:  Thyroid       Date:  2013-09-21       Impact factor: 6.568

View more
  14 in total

1.  The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders.

Authors:  Chanjuan Ma; F Stephen Hodi; Anita Giobbie-Hurder; Xiaocheng Wang; Jing Zhou; Amy Zhang; Ying Zhou; Fei Mao; Trevor E Angell; Chelsea P Andrews; Jiani Hu; Romualdo Barroso-Sousa; Ursula B Kaiser; Sara M Tolaney; Le Min
Journal:  Cancer Immunol Res       Date:  2019-05-14       Impact factor: 11.151

2.  Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival.

Authors:  Mario Giovanni Chilelli; Carlo Signorelli; Julio Rodrigo Giron Berrios; Angelo Onorato; Fabrizio Nelli; Maria Agnese Fabbri; Francesca Primi; Eleonora Marrucci; Antonella Virtuoso; Marta Schirripa; Marco Mazzotta; Enzo Maria Ruggeri
Journal:  Cancer Diagn Progn       Date:  2022-01-03

Review 3.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Authors:  Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 4.  Adverse events induced by immune checkpoint inhibitors.

Authors:  Ana Luisa Perdigoto; Harriet Kluger; Kevan C Herold
Journal:  Curr Opin Immunol       Date:  2021-02-25       Impact factor: 7.486

5.  Modeling Diagnostic Strategies to Manage Toxic Adverse Events following Cancer Immunotherapy.

Authors:  Frederik van Delft; Mirte Muller; Rom Langerak; Hendrik Koffijberg; Valesca Retèl; Daan van den Broek; Maarten IJzerman
Journal:  Med Decis Making       Date:  2021-04-05       Impact factor: 2.583

6.  Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis.

Authors:  Ploutarchos Tzoulis; Richard W Corbett; Swarupini Ponnampalam; Elly Baker; Daniel Heaton; Triada Doulgeraki; Justin Stebbing
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-03-21

Review 7.  Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism.

Authors:  Jaafar Jaafar; Eugenio Fernandez; Heba Alwan; Jacques Philippe
Journal:  Endocr Connect       Date:  2018-05       Impact factor: 3.335

8.  Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.

Authors:  Hiroshi Matsuoka; Takahiro Hayashi; Karen Takigami; Kazuyoshi Imaizumi; Ryoichi Shiroki; Naoki Ohmiya; Kazumitsu Sugiura; Kenji Kawada; Akira Sawaki; Koutaro Maeda; Yousuke Ando; Ichiro Uyama
Journal:  BMC Cancer       Date:  2020-07-14       Impact factor: 4.430

9.  Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry.

Authors:  Milena Music; Marco Iafolla; Antoninus Soosaipillai; Ihor Batruch; Ioannis Prassas; Melania Pintilie; Aaron R Hansen; Philippe L Bedard; Stephanie Lheureux; Anna Spreafico; Albiruni Abdul Razak; Lillian L Siu; Eleftherios P Diamandis
Journal:  F1000Res       Date:  2020-05-07

Review 10.  Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events-A Comprehensive Review.

Authors:  Josefien W Hommes; Rik J Verheijden; Karijn P M Suijkerbuijk; Dörte Hamann
Journal:  Front Oncol       Date:  2021-02-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.